Background: Respiratory viruses, such as influenza viruses, initially infect the upper airways but can manifest as severe lower respiratory tract infections in high-risk patients with significant morbidity and mortality. For syndromic diagnosis, several multiplex nucleic acid amplification tests have been developed for clinics, of which SureX 13 Respiratory Pathogen Multiplex Kit (ResP) can simultaneously detect 13 pathogens directly from airway secretion specimens. The organisms identified are influenza virus A, influenza virus A pdmH1N1 (2009), influenza virus A H3N2, influenza virus B, adenovirus, boca virus, rhinovirus, parainfluenza virus, coronavirus, respiratory syncytial virus, human metapneumovirus, Mycoplasma pneumoniae, and Chlamydia.
also major causes of ARIs in children. The symptoms caused by these pathogens are largely similar, thus definitive diagnosis requires effective laboratory testing. By using multiplex assay targeting these pathogens, early diagnosis can be made in a timely manner. Consequential antimicrobial or antiviral therapy may thus be administrated promptly and appropriately. 4 Most importantly, the early diagnosis of influenza viruses, which are contagious, is beneficial for early isolation of patients, thus reducing the spread of influenza viruses.
The routine clinical laboratory testing for respiratory viruses is largely conducted by direct fluorescent-antibody assays and rapid antigen tests in China. Given the poor sensitivity and complicated manual operation, these methods have been gradually replaced by nucleic acid amplification tests (NAATs), which are more sensitive and more specific. However, majority of the NAAT kits are based on real-time polymerase chain reaction (PCR), which can only detect one or two pathogens of ARIs within a single tube, thus are not syndromic testing. 5 The clinical and economic impacts of syndromic testing for respiratory pathogens have been evaluated in several studies. Overall, the implementation of syndromic testing can decrease the time of diagnosis, 4 decreased healthcare resource utilization, 6 decrease inpatient length of stay and time in isolation, 7 and improve antiviral use for influenza virus-positive patients. 8 SureX 13 Respiratory Pathogen Multiplex Kit (ResP) is a syndromic multiplex molecular test for simultaneous detection of 13 pathogens in a single tube. The aim of this study was to evaluate the application of the ResP for detection of respiratory pathogens in outpatients with flu-like manifestations.
| MATERIALS AND METHODS

| Samples
The inclusion criteria for this study were as follows: (a) patients admitted to hospitals between Feb. 2017 and Aug. 2018; (b) oropharyngeal swabs were collected from hospitals and Centers for Disease Control in Guangzhou; (c) patients had the following flu-like manifestations: (a) fever (>38°C); (b) cough or sore throat. After sampling, specimens were kept in 4°C and transferred to the laboratory for testing within one week.
| Nucleic acid extraction
The specimen was shaken vigorously for 5 minutes in phosphatebuffered saline solution, centrifuged at 9.6 g for 20 minutes, and the supernatant was aspirated. About 50 µL of RNA was extracted from 140 µL supernatant using the QIAamp Viral RNA extraction kit (QIAGEN, Hilden, Germany), according to the manufacture's instruction and was stored at −80°C. 
| Detection of influenza viruses
| Detection of other respiratory pathogens
| Multiplex detection of respiratory pathogens
The nucleic acid was subjected to multiplex amplification for all specimens using SureX 13 Respiratory Pathogen Multiplex ysis were used to determine the outcomes of testing. In brief, if the peak height of a targeted fragment size is lower than the lower peak of the signal standard, the targeted pathogen is determined negative; if the peak height of a targeted fragment size is higher than the higher peak of the signal standard, the targeted pathogen is determined positive; if the peak height of a targeted fragment size is between the higher and the lower peaks of the signal standard, the targeted pathogen is determined uncertain and the test should be repeated. 
| Statistical analysis
| RE SULTS
A total of 420 oropharyngeal swabs were enrolled from 10 hospitals and 10 CDCs in Guangzhou from 2017 to 2018. Samples were collected from a wide range of ages, with the average age of 27.2 (Table 1) . About 55% specimens were from male.
A pathogen-positive result was determined when the pathogen-specific fragment(s) was positive, as shown in Figure 1 . A negative result was determined when none of the 13 pathogen-specific fragment was positive, while the controls (huDNA, huRNA, and IC) were positive ( Figure 2 ). In this study, the ResP detected positive results in 141 samples, accounting for 33.6%, while the comparator tests detected positive results in 127 samples, with positive rate 30.2%. Among the detected pathogens, rhinovirus was the most common, followed by adenovirus and influenza virus A pdmH1N1 (2009) ( Table 2 ). Of the 420 specimens, the ResP yielded consistent positive results in 121 specimens (86.5%, 121/141), and consistent negative results in 273 specimens (97.8%, 273/279) comparing with pathogen-specific PCRs, leading to an overall agreement of 93.8%.
No specimen was detected positive with coronavirus or
Chlamydia. In six of the ten detected pathogens, the Cohen's kappa 
| D ISCUSS I ON
Multiplex PCR-based NAATs have been increasingly used for syndromic diagnosis, due to their high throughput, high sensitivity, high specificity, cost-effectiveness, and great clinical significance. [10] [11] [12] The ResP assay is based on multiplex PCR amplification and capillary electrophoretic separation of PCR amplicons by length. This technique has been used for pathogen detection and subtype classification of pediatric acute lymphoblastic leukemia. 13, 14 By comparing the results with a standard size marker of targeted pathogens, pathogens in samples can be separated and identified as expected. 15 The subtypes of most viruses were not designed to be further distinguished by this assay, except for influenza virus A. The influenza virus A pdmH1N1 (2009) and H3N2 are the two subtypes which are most popular in China recently. Therefore, a patient whose specimen is positive for influenza virus A but negative for influenza virus A pdmH1N1 (2009) or H3N2 is probably infected by an uncommon influenza virus A, such as H7N9, H5N1, H5N6 avian influenza virus A [16] [17] [18] and has to be immediately quarantined once it is confirmed. It should be noted that This assay has previously been clinically applied to detection of respiratory pathogens in hospitalized children suffered with community-acquired pneumonia (CAP) 14 or lower respiratory tract infections. 19 The assay was evaluated by comparing with Sanger sequencing, showing great performance with 100% positive prediction value (PPV) and 99.85% negative prediction value (NPV). 20 To our knowledge, this is the first study evaluating the performance of the ResP in oropharyngeal swab specimens from outpatients with ARIs.
Our study showed almost perfect kappa statistics for the ResP on rhinovirus, adenovirus, influenza virus A pdmH1N1(2009), respiratory syncytial virus, and influenza virus B, suggesting that the performance of ResP on these viruses was as effective as pathogen-specific PCRs.
On human metapneumovirus, the kappa statistics were lower than 0.8, presumably due to the small number of positive cases. Overall, this assay demonstrated 86.5% PPV and 97.8% NPV. This work suggested that the performance of ResP was sufficient enough be used for respiratory pathogen identification in outpatients with flu-like manifestations.
The major limitation of this study is the small number of human metapneumovirus, parainfluenza virus, Mycoplasma pneumoniae, boca virus, influenza virus A H3N2, coronavirus, and Chlamydia.
Further investigation is needed to evaluate the performance of ResP on these pathogens.
In conclusion, the performance of ResP showed a high-degree agreement with pathogen-specific PCRs in oropharyngeal swabs from outpatients. The implementation of ResP may facilitate the diagnosis of respiratory infections in a variety of clinical scenarios.
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